In this edition we mark the sad birthday of 5-year-old Ariel Bibas, the little redhead being held by Hamas with his baby brother and parents. We also want you to know about the courageous stand taken by Ayelet Samerano against the UNWRA secretary-general in Lausanne.
Read about how long can a hostage survive in captivity, about Turkey in NATO, the threats to Israel from Iran and Hezbollah and what the IDF says might happen.
Under the TGA (Australian Therapeutic Goods Administration) approval, PixCell's HemoScreen is cleared for use with adults and infants alike, from as early as 2 months of age.
YOKNEAM, Israel, July 1, 2020 /PRNewswire/ -- Hallura Ltd., an Israeli aesthetic medical company developing the next generation of Hyaluronic Acid (HA) Dermal Fillers, today announced that it has appointed Mr. Paul Navarre to serve as an independent director of Hallura's Board of Directors.
"We are excited to welcome Mr. Paul Navarre as he brings a wealth of knowledge and experience to Hallura's board," said Dr. Shimon Eckhouse, co-founder and Chairman of Hallura. "His exceptional track record made Paul a respected and well-known executive in the industry. Paul shares our vision on how Hallura's technology is disruptive and can transform the industry. Paul's unique insights will help guide the vision and strategic opportunities of Hallura."
Mr. Paul Navarre commented "I am very excited to join the Board of Directors. Hallura is at the forefront of the technology that will allow to access the next generation of aesthetic treatments. The great progresses Hallura did in the last two years make it an exciting time to join the company and I look forward to bringing my experience to the Board."
Paul Navarre has more than 25 years' experience in the pharmaceuticals and consumer goods industries. He was Chief Executive Officer of Ferring Holding Inc (US) between 2017 and 2020, managing activities including commercial operations, clinical development and manufacturing. Previously, as President of Allergan International, he managed a $3 billion specialty care business covering dermatology, ophthalmology, urology and neurosciences. During 10 years at Allergan, Mr. Navarre built a strong track record in the aesthetic medical market, delivering solid business results and developing multiple successful organizations. Before joining Allergan, Mr. Navarre spent 15 years at Procter & Gamble, starting in consumer goods before moving to the company's pharmaceuticals division.
About Hallura Ltd.
Hallura Ltd. brings a disruptive HA technology to the fast growing aesthetic injectables market using proprietary HA crosslinking technology, not involving BDDE. Hallura's HA dermal fillers answer the growing demand for better, safer fillers with natural and soft aesthetic results.
Founded in November 2017 by Dr. Stéphane Meunier, Mrs. Alona Gellerman, Dr. Per Hedén and Dr. Shimon Eckhouse and with its headquarters, R&D, and manufacturing in Yokneam Israel. Hallura is a portfolio company of Alon Medtech Ventures owned by Dr. Shimon Eckhouse.
Contact person: Dr. Stephane Meunier, Chief Executive Officer at Hallura; stephane@hallura.com
SOURCE Hallura Ltd.
On June 18, during Ambassador Hans Docter’s visits Yokneam high tech companies, he met with a group of 30 local startups. The Ambassador is planning a follow up visit to meet with additional companies.
HoverMast- Lite (HM-L1 and HM-L3) is Sky Sapience’s new generation tethered UAV platform. It functions as a smaller, light-weight version of the HoverMast platform that will be used with small robotic vehicles participating in the RCV/SMET program.
PITCH the recently opened high-tech co-working space in Yokneam offers entrepreneurs and startup companies unique and decorated offices, meeting rooms, a classroom and much more.
PITCH provides its ecosystem and members additional added values in strategic planning, business development and financial areas to support their success and also connects them with significant investors and partners, especially in Europe and China, in different fields of interest such as Agro-Tech, Medical & Health, Industry 4.0 and more.
For more details contact us at info@pitch.ms or by phone *5165
The company will be issuing 5,000,000 shares at a price of $14.00-$16.00 per share. In the last 12 months, InMode Ltd. generated $109.8 million in revenue and $26.1 million in net income. InMode Ltd. has a market cap of $479.6 million.
New clinical evidence of the advantages of lithotripsy treatment of benign prostatic hyperplasia (BPH) using MOSES™ Technology is being presented at the American Urological Association's (AUA) annual meeting, taking place in Chicago, May 3-6, 2019.
